Author + information
- Yoshiaki Shintani,
- Yoshimitsu Soga,
- Osamu Iida,
- Daizo Kawasaki,
- Kenji Suzuki,
- Keisuke Hirano,
- Junichi Tazaki,
- Yusuke Miyashita and
- Tomohiro Kawasaki
To examine the long term outcome of two different nitinol stent, S.M.A.R.T. or Luminexx for the iliac lesions.
This study was a multicenter retrospective analysis of a prospectively maintained database. The study enrolled consecutive patients undergoing primary stenting for de novo iliac artery stenosis between January 2005 and December 2009. A total of 1503 lesions in 1229 patients treated with S.M.A.R.T. or Luminexx primary stenting for iliac artery were enrolled. The primary endpoint was primary patency, while the secondary endpoints were primary assisted patency, secondary patency and major adverse limb events (MALE) that include all–cause death, myocardial infarction, stroke, major amputation and re–intervention.
The mean patient age was 72.4±9.0 years; the mean follow–up interval was 27.3±17.5 months. The mean stent length was 57.1±37.3 mm and 56.8±31.3 mm in S.M.A.R.T. and Luminexx, (p=0.890, respectively). The primary patency at 5 years after S.M.A.R.T. and Luminexx was not significantly different (79.7% and 80.0%, p=0.603, respectively). Assisted primary patency and secondary patency rate was not significantly different (92.4% and 93.0%, p= 0.665, 98.9% and 98.5%, p=0.860). In addition, the MALE rate was not significantly different (30.3% and 22.2%, p= 0.081).
The use of stent for the iliac artery provided good long–term patency for 5 years of follow–up regardless of whether S.M.A.R.T. or Luminexx were used.
Poster Sessions, Expo North
Sunday, March 10, 2013, 3:45 p.m.–4:30 p.m.
Session Title: Vascular Medicine: Endovascular Therapy III
Abstract Category: 34. Vascular Medicine: Endovascular Therapy
Presentation Number: 1253–164
- 2013 American College of Cardiology Foundation